| 0.038 0 (0%) | 01-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.04 | 1-year : | 0.04 |
| Resists | First : | 0.03 | Second : | 0.03 |
| Pivot price | 0.03 | |||
| Supports | First : | 0.03 | Second : | 0.03 |
| MAs | MA(5) : | 0.03 | MA(20) : | 0.03 |
| MA(100) : | 0.03 | MA(250) : | 0.04  |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 41 | |||
| 52-week | High : | 0.1 | Low : | 0.02 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BGXX ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 0.04 - 0.04 | 0.04 - 0.04 |
| Low: | 0.04 - 0.04 | 0.04 - 0.04 |
| Close: | 0.04 - 0.04 | 0.04 - 0.04 |
Bright Green Corporation grows, manufactures, and sells cannabis and cannabis-related products legally under federal and state laws for research, pharmaceutical applications, and export. The company was incorporated in 2019 and is based in Fort Lauderdale, Florida.
Thu, 08 Jan 2026
Lynn Stockwell and Bright Green Corporation File $3 Billion - GlobeNewswire
Mon, 15 Sep 2025
10,000 Tesla Robots to Power US Pharma Manufacturing: Bright Green's Merger Creates Sovereign Drug Platform - Stock Titan
Mon, 15 Sep 2025
Bright Green Corporation Merges with PharmAGRI Capital Partners; Lynn Stockwell Appointed CEO and Chairwoman - GlobeNewswire
Wed, 16 Jul 2025
The DEA's BILLION Dollar Marijuana Scandal: A DEA Regulatory Betrayal of Science and Public Trust - Newswire.com
Fri, 21 Mar 2025
Bright Green Unveils Massive $2B Cannabis Strategy with Zero Shareholder Dilution - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 191 (M) |
| Shares Float | 72 (M) |
| Held by Insiders | 62.5 (%) |
| Held by Institutions | 0.3 (%) |
| Shares Short | 746 (K) |
| Shares Short P.Month | 737 (K) |
| EPS | -0.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.05 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18.6 % |
| Return on Equity (ttm) | -73.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.76 |
| PEG Ratio | 0 |
| Price to Book value | 0.75 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|